GW Pharmaceuticals plc logo
GW Pharmaceuticals plc GWPH

GW Pharmaceuticals plc Financial Ratios 2011-2026 | GWPH

Annual Financial Ratios GW Pharmaceuticals plc

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-82.3 -4649.0 -12.4 -15.2 -31.8 -24.0 -51.9 -52.7 - -

P/S

9.1 134.7 288.2 243.3 196.3 37.5 25.3 8.8 - -

EV/EBITDA

-110.2 -379.2 -11.9 -12.4 -15.2 -13.7 -27.8 -21.3 - -

PEG

-0.15 47.64 -0.24 -0.17 -2.73 -0.17 -0.39 0.2 - -

P/B

6.5 57.8 8.8 7.2 5.1 4.4 4.8 6.8 - -

P/CF

-86.4 -252.7 -13.8 -15.8 -21.6 -16.6 -38.3 -24.7 - -

ROE %

-7.84 -1.24 -71.10 -47.34 -15.97 -18.17 -9.24 -12.85 - -

ROA %

-6.19 -1.02 -60.17 -39.56 -14.05 -15.38 -7.58 -7.72 - -

ROCE %

-6.64 -15.49 -66.87 -50.00 -26.82 -24.21 -12.96 -22.65 - -

DSO

49.3 57.3 60.8 1054.9 822.4 178.7 81.1 51.8 - -

DIO

1255.9 1147.8 1162.3 437.5 570.3 663.1 846.4 1333.3 - -

DPO

212.7 134.1 594.0 598.6 460.8 529.1 415.0 970.6 - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company GW Pharmaceuticals plc, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.88 -1.73 % $ 6.47 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.48 0.81 % $ 3.73 B usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 101.39 -0.66 % $ 27.2 B germanyGermany
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.06 -0.98 % $ 434 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.08 -1.45 % $ 2.94 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.49 4.58 % $ 397 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.92 -0.14 % $ 4.81 M israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.7 -1.45 % $ 114 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.06 -3.21 % $ 12.9 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.83 -2.92 % $ 284 M usaUSA